Loskog A

CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling.

Naseri S, Cordova MM, Wenthe J, ..., Loskog A, Ullenhag GJ

J. Cell. Mol. Med. 28 (7) e18162 [2024-04-00; online 2024-03-18]

Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients.

Sarén T, Ramachandran M, Gammelgård G, ..., Enblad G, Essand M

Clin. Cancer Res. 29 (20) 4139-4152 [2023-10-13; online 2023-08-04]

Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors.

Irenaeus S, Hellström V, Wenthe J, ..., Loskog A, Ullenhag GJ

Cancer Gene Ther. 28 (10-11) 1188-1197 [2021-11-00; online 2020-12-14]

Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40.

Wenthe J, Naseri S, Hellström AC, ..., Eriksson E, Loskog A

Cancer Gene Ther. 27 (12) 948-959 [2020-12-00; online 2020-05-01]

Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients.

Schiza A, Irenaeus S, Ortiz-Nieto F, ..., Ullenhag GJ, Ahlström H

Sci Rep 9 (1) 18069 [2019-12-02; online 2019-12-02]

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.

Enblad G, Karlsson H, Gammelgård G, ..., Hagberg H, Loskog A

Clin. Cancer Res. 24 (24) 6185-6194 [2018-12-15; online 2018-08-10]